{"groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"FG000","title":"Twice-weekly Kyprolis (Carfilzomib) + Lenalidomide + Dexamethsone (KRd) 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"FG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"Decision by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"25"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"228"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"228"}],"type":"Received Carfilzomib"},{"achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"150"}],"type":"Completed 12 Cycles Carfilzomib"},{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"228"}],"type":"Received Lenalidomide"},{"achievements":[{"groupId":"FG000","numSubjects":"226"},{"groupId":"FG001","numSubjects":"228"}],"type":"Received Dexamethasone"},{"achievements":[{"groupId":"FG000","numSubjects":"231"},{"groupId":"FG001","numSubjects":"223"}],"comment":"Participants were analyzed according to the treatment arm corresponding to the actual treatment received.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"197"},{"groupId":"FG001","numSubjects":"191"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"37"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with relapsed or refractory multiple myeloma were randomized in a 1:1 ratio to receive once-weekly or twice-weekly carfilzomib. Randomization was stratified by original International Staging System (ISS) stage at the time of study entry (stage 1 or 2 versus stage 3), prior lenalidomide treatment (yes versus no), prior proteasome inhibitor treatment (yes versus no), and prior anti-CD38 exposure (yes versus no).","recruitmentDetails":"Participants were enrolled at 80 study centers in Europe, Japan, and the United States, and participated from 08 May 2019 to 31 March 2023."}